Changes in the soluble mucosal immune environment during genital herpes outbreaks

Journal of Acquired Immune Deficiency Syndromes

Volumn 61, Issue 2, 2012, Pages 194-202

  Keller, Marla J ^a   Madan, Rebecca P ^a   Shust, Gail ^a   Carpenter, Colleen A ^a   Torres, N Merna ^a   Cho, Sylvia ^a   Khine, Hnin ^a   Huang, Meei Li ^b   Corey, Lawrence ^b   Kim, Mimi ^a   Herold, Betsy C ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

herpes simplex virus; human immunodeficiency virus; soluble mucosal immunity

Indexed keywords

ACICLOVIR;

ADULT; ANTIMICROBIAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; GENITAL HERPES; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; MEDIATOR; PRIORITY JOURNAL; SERODIAGNOSIS; SHORT COURSE THERAPY; VAGINAL LAVAGE;

ACYCLOVIR; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CERVIX MUCUS; DISEASE OUTBREAKS; FEMALE; HERPES GENITALIS; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS; MIDDLE AGED; VAGINAL DOUCHING; YOUNG ADULT;

EID: 84866994975     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31826867ae     Document Type: Article

References (43)

1. Roberts C. Genital herpes in young adults: changing sexual behaviours, epidemiology and management. Herpes. 2005;12:10-14.
2. Roberts CM, Pfister JR, Spear SJ. Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sex Transm Dis. 2003;30:797-800.
3. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA. 2006;296: 964-973.
4. Nagot N, Ouedraogo A, Foulongne V, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med. 2007;356:790-799.
5. Chen L, Jha P, Stirling B, et al. Sexual risk factors for HIV infection in early and advanced HIV epidemics in sub-Saharan Africa: systematic overview of 68 epidemiological studies. PLoS One. 2007;2:e1001.
6. Freeman EE, Weiss HA, Glynn JR, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS. 2006;20:73-83.
7. Zhu J, Hladik F, Woodward A, et al. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med. 2009;15:886-892.
8. Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371:2109-2119.
9. Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med. 2010;362:427-439.
10. John M, Keller MJ, Fam EH, et al. Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection. J Infect Dis. 2005; 192:1731-1740.
11. Shust GF, Cho S, Kim M, et al. Female genital tract secretions inhibit herpes simplex virus infection: correlation with soluble mucosal immune mediators and impact of hormonal contraception. Am J Reprod Immunol. 2010;63:110-119.
12. Ghosh M, Fahey JV, Shen Z, et al. Anti-HIV activity in cervical-vaginal secretions from HIV-positive and-negative women correlate with innate antimicrobial levels and IgG antibodies. PLoS One. 2010;5:e11366.
13. Wang W, Owen SM, Rudolph DL, et al. Activity of alpha-and theta-defensins against primary isolates of HIV-1. J Immunol. 2004; 173:515-520.
14. Hazrati E, Galen B, Lu W, et al. Human alpha-and beta-defensins block multiple steps in herpes simplex virus infection. J Immunol. 2006;177: 8658-8666.
15. Levinson P, Kaul R, Kimani J, et al. Levels of innate immune factors in genital fluids: association of alpha defensins and LL-37 with genital infections and increased HIV acquisition. AIDS. 2009;23:309-317.
16. Tanton C, Weiss HA, LeGoff J, et al. Patterns of herpes simplex virus shedding over 1 month and the impact of acyclovir and HIV in HSV-2-seropositive women in Tanzania. Sex Transm Infect. 2011;87:406-411.
17. Jerome KR, Huang ML, Wald A, et al. Quantitative stability of DNA after extended storage of clinical specimens as determined by real-time PCR. J Clin Microbiol. 2002;40:2609-2611.
18. Keller MJ, Madan RP, Torres NM, et al. A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS One. 2011; 6:e16475.
19. Peng T, Zhu J, Klock A, et al. Evasion of the mucosal innate immune system by herpes simplex virus type 2. J Virol. 2009;83:12559-12568.
20. Venkataraman N, Cole AL, Svoboda P, et al. Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid. J Immunol. 2005;175:7560-7567.
21. Keller MJ, Guzman E, Hazrati E, et al. PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. AIDS. 2007;21:467-476.
22. Valore EV, Park CH, Igreti SL, et al. Antimicrobial components of vaginal fluid. Am J Obstet Gynecol. 2002;187:561-568.
23. Belec L, Meillet D, Levy M, et al. Dilution assessment of cervicovaginal secretions obtained by vaginal washing for immunological assays. Clin Diagn Lab Immunol. 1995;2:57-61.
24. Mitchell C, Paul K, Agnew K, et al. Estimating volume of cervicovaginal secretions in cervicovaginal lavage fluid collected for measurement of genital HIV-1 RNA levels in women. J Clin Microbiol. 2011;49:735-736.
25. Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med. 2000;342:844-850.
26. Madan RP, Carpenter C, Fiedler T, et al. Altered biomarkers of mucosal immunity and reduced vaginal lactobacillus concentrations in sexually active female adolescents PLoS One. 2012;7:e40415. Published ahead of print July 10, 2012.
27. Nagot N, Ouedraogo A, Konate I, et al. Roles of clinical and subclinical reactivated herpes simplex virus type 2 infection and human immunodeficiency virus type 1 (HIV-1)-induced immunosuppression on genital and plasma HIV-1 levels. J Infect Dis. 2008;198:241-249.
28. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med. 2004;350:11-20.
29. Fakioglu E, Wilson SS, Mesquita PM, et al. Herpes simplex virus down-regulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism. J Virol. 2008;82:9337-9344.
30. Burgener A, Rahman S, Ahmad R, et al. Comprehensive proteomic study identifies serpin and cystatin antiproteases as novel correlates of HIV-1 resistance in the cervicovaginal mucosa of female sex workers. J Pro-teome Res. 2011;10:5139-5149.
31. Nagot N, Ouedraogo A, Defer MC, et al. Association between bacterial vaginosis and Herpes simplex virus type-2 infection: implications for HIV acquisition studies. Sex Transm Infect. 2007;83:365-368.
32. Cherpes TL, Melan MA, Kant JA, et al. Genital tract shedding of herpes simplex virus type 2 in women: effects of hormonal contraception, bacterial vaginosis, and vaginal group B Streptococcus colonization. Clin Infect Dis. 2005;40:1422-1428.
33. Valore EV, Wiley DJ, Ganz T. Reversible deficiency of antimicrobial polypeptides in bacterial vaginosis. Infect Immun. 2006;74:5693-5702.
34. Fredricks DN, Fiedler TL, Thomas KK, et al. Targeted PCR for detection of vaginal bacteria associated with bacterial vaginosis. J Clin Microbiol. 2007;45:3270-3276.
35. Marrazzo JM, Martin DH, Watts DH, et al. Bacterial vaginosis: identifying research gaps proceedings of a workshop sponsored by DHHS/NIH/NIAID. Sex Transm Dis. 2010;37:732-744.
36. Gupta K, Hillier SL, Hooton TM, et al. Effects of contraceptive method on the vaginal microbial flora: a prospective evaluation. J Infect Dis. 2000;181:595-601.
37. Abu-Raddad LJ, Magaret AS, Celum C, et al. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS One. 2008;3:e2230.
38. Corey L. Synergistic copathogens-HIV-1 and HSV-2. N Engl J Med. 2007;356:854-856.
39. Koelle DM, Wald A. Herpes simplex virus: the importance of asymptomatic shedding. J Antimicrob Chemother. 2000;45(suppl T3):1-8.
40. Mbopi-Keou FX, Gresenguet G, Mayaud P, et al. Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention. J Infect Dis. 2000;182:1090-1096.
41. Mostad SB, Kreiss JK, Ryncarz AJ, et al. Cervical shedding of herpes simplex virus in human immunodeficiency virus-infected women: effects of hormonal contraception, pregnancy, and vitamin A deficiency. J Infect Dis. 2000;181:58-63.
42. Mugo N, Dadabhai SS, Bunnell R, et al. Prevalence of herpes simplex virus type 2 infection, human immunodeficiency virus/herpes simplex virus type 2 coinfection, and associated risk factors in a national, population-based survey in Kenya. Sex Transm Dis. 2011;38: 1059-1066.
43. Reynolds SJ, Risbud AR, Shepherd ME, et al. Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India. J Infect Dis. 2003;187:1513-1521.